Abstract:Background Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia. Methods One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and for BCR/ABL. Deletions in IKZF1 were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis and multiplex ligation-dependent probe amplification (MLPA). BCR/ABL was detected using RQ-PCR. All subjects received chemotherapy and some also received an allotransplant and tyrosine kinase-inhibitors. Multivariate analyses were done to identify associations between IKZF1 deletion and other variables on non-relapse mortality (NRM), cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and survival. Results Amongst subjects achieving complete remission those with IKZF1 deletion had similar 5-year non-relapse mortality (NRM) (11 % [2–20 %] vs. 16 % [4–28 %]; P = 0.736), a higher 5-year cumulative incidence of relapse (CIR) (55 % [35–76 %] vs. 25 % [12–38 %]; P = 0.004), and worse 5-year leukemia-free survival (LFS) (33 % [16–52 %] vs. 59 % [42–73 %]; P = 0.012) and survival (48 % [33–62 %] vs. 75 % [57–86 %]; P = 0.002). In multivariate analyses IKZF1 deletion was associated with an increased relapse (relative risk [RR] =2.7, [1.4–5.2]; P = 0.002), a higher risk of treatment-failure (inverse of LFS; RR = 2.1, [1.2–3.6]; P = 0.007) and a higher risk of death ( RR = 2.8, [1.5–5.5]; P = 0.002). The adverse impact of IKZF1 deletion on outcomes was stronger in subjects without vs. with BCR-ABL1 and in subjects receiving chemotherapy-only vs. an allotransplant. Conclusions IKZF1 deletion was independently-associated with a higher relapse risk and worse LFS and survival in adults with common B-cell ALL after adjusting for other prognostic variables and differences in therapies. These data suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons without BCR-ABL1 and those receiving chemotherapy-only. Transplants appear to overcome the adverse impact of IKZF1 deletion on therapy-outcomes but confirmation in a randomized study is needed. The trial was registered in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007–1007).

CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia

Childhood Acute B-Lineage Lymphoblastic Leukemia with CDKN2A/B Deletion is a Distinct Entity with Adverse Genetic Features and Poor Clinical Outcomes.

Allogeneic haematopoietic stem cell transplantation might overcome the poor prognosis of adolescents and adult patients with T-lineage acute lymphoblastic leukaemia and CDKN2 deletion

Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia

Prognostic Significance of CDKN2A/B Deletions in Acute Lymphoblastic Leukaemia: a Meta-Analysis

Allogeneic Hematopoietic Stem Cell Transplantation Improves the Prognosis of P16-Deleted Adult Patients with Acute Lymphoblastic Leukemia

Gene Deletions And Prognostic Values In B-Linage Acute Lymphoblastic Leukemia

[Long-Term Outcome of Childhood T-cell Acute Lymphoblastic Leukemia Treated with Modified National Protocol of Childhood Leukemia in China-acute Lymphoblastic Leukemia 2008].

CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia

Prognostic Significance of Copy Number Alterations Detected by Multi-Link Probe Amplification of Multiple Genes in Adult Acute Lymphoblastic Leukemia.

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia

High CD38 Expression in Childhood T-cell Acute Lymphoblastic Leukemia is Not Associated with Prognosis.

The Functional Role of Inherited CDKN2A Variants in Childhood Acute Lymphoblastic Leukemia

Clinical Analysis of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with P16gene Deletion

A meta-analysis of the prognostic significance of CDKN deletions in acute lymphoblastic leukaemia

Spectrum and Clinical Features of Gene Mutations in Chinese Pediatric Acute Lymphoblastic Leukemia

Clinical Features and Prognostic Impact of TCF3–PBX1 in Childhood Acute Lymphoblastic Leukemia: A Single-Center Retrospective Study of 837 Patients from China

The Prevalent, Features and Prognostic Impact of Deletion P16 in Patients with Adult Acute Lymphoblastic Leukemia

Quantitative Analysis of IKZF1 Gene Deletions in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia: Higher Levels Are Associated with a Poorer Prognosis.

Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia.

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).